针对携带Phe508del CFTR纯合突变的囊性纤维化患者使用鲁马卡托-依伐卡托。 - Suppr

Suppr

超能文献

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

作者信息

Wainwright Claire E, Elborn J Stuart, Ramsey Bonnie W

出版信息

N Engl J Med. 2015 Oct 29;373(18):1783-4. doi: 10.1056/NEJMc1510466.

DOI:10.1056/NEJMc1510466

PMID:26510034

Abstract

摘要

相似文献

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

N Engl J Med. 2015 Oct 29;373(18):1783-4. doi: 10.1056/NEJMc1510466.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

N Engl J Med. 2015 Oct 29;373(18):1783. doi: 10.1056/NEJMc1510466.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

Lancet Respir Med. 2014 Jul;2(7):527-38. doi: 10.1016/S2213-2600(14)70132-8. Epub 2014 Jun 24.

Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.

Drugs Today (Barc). 2016 Apr;52(4):229-37. doi: 10.1358/dot.2016.52.4.2467205.

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.

Lancet Respir Med. 2016 Aug;4(8):617-626. doi: 10.1016/S2213-2600(16)30121-7. Epub 2016 Jun 10.

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.

Lancet Respir Med. 2017 Jul;5(7):557-567. doi: 10.1016/S2213-2600(17)30215-1. Epub 2017 Jun 9.

Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.

Value Health. 2017 Dec;20(10):1329-1335. doi: 10.1016/j.jval.2017.06.014. Epub 2017 Aug 1.

The stony road to phe508del CFTR pharmacotherapy: smoothing the first rock.

Lancet Respir Med. 2014 Jul;2(7):508-9. doi: 10.1016/S2213-2600(14)70136-5. Epub 2014 Jun 24.

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

Lancet Respir Med. 2017 Feb;5(2):107-118. doi: 10.1016/S2213-2600(16)30427-1. Epub 2016 Dec 21.

引用本文的文献

The effect of modulators on lung function following inpatient treatment for CF exacerbations.

Front Pediatr. 2025 Aug 21;13:1654122. doi: 10.3389/fped.2025.1654122. eCollection 2025.

Deleterious effect of on F508del-CFTR rescued by elexacaftor/tezacaftor/ivacaftor is clinical strain-dependent in patient-derived nasal cells.

ERJ Open Res. 2025 May 27;11(3). doi: 10.1183/23120541.00970-2024. eCollection 2025 May.

Sex disparities in cystic fibrosis in the era of highly effective modulator treatment.

BMC Pulm Med. 2025 May 2;25(1):212. doi: 10.1186/s12890-025-03621-0.

Recent developments in cystic fibrosis drug discovery: where are we today?

Expert Opin Drug Discov. 2025 May;20(5):659-682. doi: 10.1080/17460441.2025.2490250. Epub 2025 Apr 13.

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.

Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251323194. doi: 10.1177/17534666251323194. Epub 2025 Mar 31.

Comparative Efficacy of CFTR Modulators: A Network Meta-analysis.

Lung. 2025 Mar 18;203(1):49. doi: 10.1007/s00408-025-00802-w.

Reply to Martin and Grasemann: Is There a Role for Lumacaftor/Ivacaftor in Young Children with Cystic Fibrosis?

Ann Am Thorac Soc. 2025 Mar;22(3):469-470. doi: 10.1513/AnnalsATS.202411-1237LE.

Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real-Life Study.

Pediatr Pulmonol. 2025 Jan;60(1):e27473. doi: 10.1002/ppul.27473.

Exploring Therapeutic Strategies for Pediatric Cystic Fibrosis: An In-Depth Comparative Review.

Cureus. 2024 Oct 20;16(10):e71913. doi: 10.7759/cureus.71913. eCollection 2024 Oct.

The ageing of people living with cystic fibrosis: what to expect now?

Eur Respir Rev. 2024 Oct 30;33(174). doi: 10.1183/16000617.0071-2024. Print 2024 Oct.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验